−1.27USD
−90.21 MUSD
41.12 M
About Terns Pharmaceuticals, Inc.
Sector
Industry
CEO
Amy L. Burroughs
Website
Headquarters
Foster City
Employees (FY)
66
Founded
2017
ISIN
US8808811074
FIGI
BBG00KK1SJ08
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TERN is 4.59 USD — it has increased by 1.10% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Terns Pharmaceuticals, Inc. stocks are traded under the ticker TERN.
Terns Pharmaceuticals, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
TERN stock is 6.31% volatile and has beta coefficient of −0.45. Check out the list of the most volatile stocks — is Terns Pharmaceuticals, Inc. there?
One year price forecast for Terns Pharmaceuticals, Inc. has a max estimate of 22.00 USD and a min estimate of 5.50 USD.
TERN earnings for the last quarter are −0.42 USD whereas the estimation was −0.31 USD which accounts for −37.46% surprise. Estimated earnings for the next quarter are −0.29 USD. See more details about Terns Pharmaceuticals, Inc. earnings.
Yes, you can track Terns Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
TERN stock has fallen by 16.39% compared to the previous week, the month change is a 23.37% fall, over the last year Terns Pharmaceuticals, Inc. has showed a 61.85% decrease.
TERN net income for the last quarter is −21.02 M USD, while the quarter before that showed −29.77 M USD of net income which accounts for 29.39% change. Track more Terns Pharmaceuticals, Inc. financial stats to get the full picture.
Today Terns Pharmaceuticals, Inc. has the market capitalization of 293.52 M, it has decreased by 17.02% over the last week.
No, TERN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TERN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Terns Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 66.00 employees. See our rating of the largest employees — is Terns Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Terns Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Terns Pharmaceuticals, Inc. stock shows the strong sell signal. See more of Terns Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Terns Pharmaceuticals, Inc. future price: according to them, TERN price has a max estimate of 22.00 USD and a min estimate of 5.50 USD. Read a more detailed Terns Pharmaceuticals, Inc. forecast: see what analysts think of Terns Pharmaceuticals, Inc. and suggest that you do with its stocks.